Activity Provided By:

Paradigm Medical Communications, LLC.

Exploring Nuances Among Targeted and Immune Checkpoint Therapies in Melanoma: Focus on Mechanisms, BRAF Mutation, and Achieving a Durable Response

Overview / Abstract:	The treatment of advanced melanoma has shifted dramatically since the introduction of immune checkpoint inhibitors and BRAF/MEK inhibitors. Now, community oncology clinicians have multiple treatment options for their patients with stage III and IV disease that include both targeted and immunotherapies. However, treatment selection is highly complex, requiring consideration of multiple patient-, disease-, and treatment-related variables. It is therefore critical to provide community oncology clinicians with education about optimal treatment selection for immune checkpoint inhibitors with a discussion of how their mechanisms of action (MOA) differ from that of targeted therapies; the latest clinical trial data that provide clues to nuances between and within drug classes; selecting agents that can provide a durable response; sequencing of agents; and differences in safety profiles. Importantly, community oncology clinicians must also be adept at recognizing and effectively managing immune-related adverse events (irAEs).
Expiration	Feb 03, 2021
Discipline(s)	Nurse Practitioner , Physician CME, Physician Assistant CME
Format	Online, Webinar / Webcast / Video
Credits / Hours	1.0
Accreditation	Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Presenters / Authors / Faculty	Faculty Presenter Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Philadelphia, PA Steering Committee Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Philadelphia, PA Ragini R. Kudchadkar, MD Associate Professor Department of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, GA
Activity Specialities / Related Topics	Oncology / Cancer / Radiation Therapy
Sponsors / Supporters / Grant Providers	This activity is supported by an educational grant from Bristol-Myers Squibb.
Keywords / Search Terms	Paradigm Medical Communications, LLC. Melanoma, BRAF/MEK inhibitors, Oncology, immune-related adverse events Free CE CME Live CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map